Display options
Cite
Romano A, Vetro C, Caocci G, et al. Immunological deregulation in classic hodgkin lymphoma. Mediterr J Hematol Infect Dis. 2014;6(1):e2014039doi: 10.4084/MJHID.2014.039.
Romano, A., Vetro, C., Caocci, G., Greco, M., Parrinello, N. L., Di Raimondo, F., & La Nasa, G. (2014). Immunological deregulation in classic hodgkin lymphoma. Mediterranean journal of hematology and infectious diseases, 6(1), e2014039. https://doi.org/10.4084/MJHID.2014.039
Romano, Alessandra, et al. "Immunological deregulation in classic hodgkin lymphoma." Mediterranean journal of hematology and infectious diseases vol. 6,1 (2014): e2014039. doi: https://doi.org/10.4084/MJHID.2014.039
Romano A, Vetro C, Caocci G, Greco M, Parrinello NL, Di Raimondo F, La Nasa G. Immunological deregulation in classic hodgkin lymphoma. Mediterr J Hematol Infect Dis. 2014 Jun 01;6(1):e2014039. doi: 10.4084/MJHID.2014.039. eCollection 2014. PMID: 24959336; PMCID: PMC4063611.
Copy Download .nbib Format: NLM
Share it on

Mediterr J Hematol Infect Dis. 2014 Jun 01;6(1):e2014039. doi: 10.4084/MJHID.2014.039. eCollection 2014.

Immunological deregulation in classic hodgkin lymphoma.

Mediterranean journal of hematology and infectious diseases

Alessandra Romano, Calogero Vetro, Giovanni Caocci, Marianna Greco, Nunziatina Laura Parrinello, Francesco Di Raimondo, Giorgio La Nasa

Affiliations

  1. Division of Haematology, Azienda Ospedaliera "Policlinico-Vittorio Emanuele", University of Catania. Via Citelli 6, 95124 Catania, Italy.
  2. Hematology Unit, Department of Medical Sciences "Mario Aresu," University of Cagliari, Italy.

PMID: 24959336 PMCID: PMC4063611 DOI: 10.4084/MJHID.2014.039

Abstract

Classic Hodgkin Lymphoma (cHL) has a unique histology since only a few neoplastic cells are surrounded by inflammatory accessory cells that in the last years have emerged as crucial players in sustaining the course of disease. In addition, recent studies suggest that the abnormal activity of these inflammatory cells (such as deregulation in regulatory T cells signaling, expansion of myeloid derived suppressor cells, HLA-G signaling and natural killer cells dysfunction) may have prognostic significance. This review is focused on summarizing recent advanced in immunological defects in cHL with translational implications.

References

  1. Hum Pathol. 2009 Dec;40(12):1715-22 - PubMed
  2. Clin Cancer Res. 2013 Feb 1;19(3):731-42 - PubMed
  3. Immunol Lett. 2013 Sep-Oct;155(1-2):56-9 - PubMed
  4. Am J Surg Pathol. 2008 Aug;32(8):1252-7 - PubMed
  5. J Leukoc Biol. 2007 Sep;82(3):576-84 - PubMed
  6. Expert Opin Ther Targets. 2008 Jun;12(6):769-82 - PubMed
  7. Blood. 2004 Mar 1;103(5):1755-62 - PubMed
  8. Hum Pathol. 2010 Dec;41(12):1726-34 - PubMed
  9. Cancer Immunol Immunother. 2009 Jan;58(1):85-94 - PubMed
  10. Clin Exp Immunol. 1977 Jul;29(1):30-5 - PubMed
  11. Eur J Immunol. 2010 Dec;40(12):3317-20 - PubMed
  12. PLoS One. 2013 Nov 21;8(11):e79502 - PubMed
  13. Blood. 2009 Mar 19;113(12):2765-3775 - PubMed
  14. Blood. 2007 Aug 15;110(4):1326-9 - PubMed
  15. J Leukoc Biol. 2011 Feb;89(2):311-7 - PubMed
  16. Int Immunopharmacol. 2009 May;9(5):590-2 - PubMed
  17. Clin Dev Immunol. 2012;2012:756353 - PubMed
  18. Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):13134-9 - PubMed
  19. Adv Hematol. 2011;2011:142395 - PubMed
  20. Eur J Immunol. 2002 May;32(5):1205-11 - PubMed
  21. Hematology Am Soc Hematol Educ Program. 2012;2012:328-34 - PubMed
  22. Eur J Haematol. 2012 Apr;88(4):292-305 - PubMed
  23. Br J Haematol. 2008 Mar;140(5):527-36 - PubMed
  24. Blood. 2003 Jan 15;101(2):681-9 - PubMed
  25. Mod Pathol. 2002 Aug;15(8):838-44 - PubMed
  26. Am J Pathol. 1994 Jul;145(1):37-41 - PubMed
  27. J Immunol. 2010 Mar 15;184(6):3106-16 - PubMed
  28. Blood. 2008 Mar 15;111(6):3220-4 - PubMed
  29. Immunology. 2009 Mar;126(3):436-45 - PubMed
  30. Haematologica. 2012 Mar;97(3):410-5 - PubMed
  31. Am J Pathol. 1999 Jun;154(6):1685-91 - PubMed
  32. Immunol Today. 2000 Nov;21(11):573-83 - PubMed
  33. Blood. 2012 Feb 9;119(6):1479-89 - PubMed
  34. Eur J Immunol. 2010 Nov;40(11):2969-75 - PubMed
  35. Am J Pathol. 2008 Jul;173(1):195-204 - PubMed
  36. Blood. 2007 Nov 1;110(9):3226-33 - PubMed
  37. Clin Cancer Res. 2008 Feb 1;14(3):685-91 - PubMed
  38. Blood. 2013 Apr 25;121(17):3431-3 - PubMed
  39. Cytometry B Clin Cytom. 2008 Jan;74(1):1-8 - PubMed
  40. Mol Ther. 2013 Apr;21(4):895-903 - PubMed
  41. Oncogene. 2008 Oct 6;27(45):5944-58 - PubMed
  42. Cytometry B Clin Cytom. 2008 Jul;74(4):227-35 - PubMed
  43. Blood. 2002 Jun 15;99(12):4283-97 - PubMed
  44. Tissue Antigens. 2008 Mar;71(3):219-26 - PubMed
  45. Cancer Res. 2009 Feb 15;69(4):1553-60 - PubMed
  46. Int Rev Exp Pathol. 1992;33:141-64 - PubMed
  47. Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8856-61 - PubMed
  48. Cancer Res. 2005 Jul 1;65(13):5516-9 - PubMed
  49. Blood. 2009 Jun 18;113(25):6392-402 - PubMed
  50. Nature. 2007 May 24;447(7143):482-6 - PubMed
  51. Haematologica. 2012 Feb;97(2):262-9 - PubMed
  52. Blood. 2006 Jul 15;108(2):662-8 - PubMed
  53. Haematologica. 2012 Jun;97(6):e21-3; author reply e24 - PubMed
  54. N Engl J Med. 2010 Mar 11;362(10):875-85 - PubMed
  55. Cancer Res. 2006 Jun 1;66(11):5716-22 - PubMed
  56. J Clin Oncol. 2011 May 10;29(14):1812-26 - PubMed
  57. Nat Rev Immunol. 2012 Mar 22;12(4):253-68 - PubMed
  58. Trends Immunol. 2011 Jan;32(1):19-25 - PubMed

Publication Types